Physician profile
Seth Wayne Miller
NPI 1346521945
$15,929.90
in general payments reported to CMS, 2019-2025
36 companies · $3,840 in 2025
The $3,840 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,443 · 2022: $2,817 · 2023: $3,372 · 2024: $3,458 · 2025: $3,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $67.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,602.86 |
| Education | $67.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,853.18 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,376.82 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,753.47 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,246.96 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $776.65 | 2021-2025 | |
| Genzyme Corporation | $679.36 | 2022-2025 | |
| Daiichi Sankyo INC. | $465.37 | 2021-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $371.68 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $321.52 | 2022-2024 | Linzess |
| Celgene Corporation | $318.31 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $279.13 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $263.73 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $237.88 | 2023-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $236.84 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $214.55 | 2021-2023 | Movantik, Talicia, Aemcolo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $209.99 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $160.98 | 2021-2025 | Gimoti |
| Janssen Scientific Affairs, LLC | $132.39 | 2021-2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $132.04 | 2021-2023 | |
| Ethicon US, LLC | $108.13 | 2021-2022 | |
| Ardelyx, INC. | $98.26 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $87.71 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $84.89 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $81.07 | 2023 | Zeposia |
| Fresenius Kabi USA, LLC | $70.77 | 2023 | Idacio |
| Novo Nordisk INC | $55.03 | 2023-2025 | Wegovy |
| Qol Medical, LLC | $49.11 | 2023 | Sucraid |
| Gilead Sciences, INC. | $42.92 | 2025 | |
| Amgen INC. | $41.63 | 2021 | |
| Ferring Pharmaceuticals INC. | $36.75 | 2022-2024 | Rebyota |
| Amag Pharmaceuticals, INC. | $35.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.12 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $26.63 | 2021-2022 | |
| Sandoz INC. | $20.42 | 2023 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $17.99 | 2023 | Terlivaz |
| Organon LLC | $11.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.